UK Unveils Weight Loss Jabs for Unemployed to Boost Health and Economy
The UK government plans to provide weight loss injections to unemployed people with obesity to improve public health and economy. Prime Minister Rishi Sunak believes this initiative can help return people to work and ease NHS pressures. With a £279 million investment from Lilly, trials will explore the effectiveness of these jabs in reducing obesity-related illness and NHS strain.
The UK government is considering providing weight loss injections to unemployed individuals living with obesity as part of efforts to improve public health and stimulate the economy.
Speaking to the BBC, Prime Minister Rishi Sunak emphasized the potential of such measures to aid individuals in returning to work, while reducing the strain on the NHS.
Health Secretary Wes Streeting noted these injections, including drugs like Mounjaro, could revolutionize treatment and alleviate NHS burdens, which see £11bn annually due to obesity-related illnesses.
A £279 million investment from pharmaceutical giant Lilly was announced at an international summit, with real-world trials to be conducted by Health Innovation Manchester and Lilly.
These trials will assess the impact of weight-loss jabs on employment and NHS usage.
Streeting further stressed that although the jabs could decrease absence due to obesity-related sickness, individuals must still prioritize healthy living.
Existing medicines, such as Wegovy and Ozempic, are administered via injection to aid appetite suppression, but experts advise that they should supplement, not replace, a healthy lifestyle.
NHS chief Amanda Pritchard described these drugs as potential 'game-changers', with the capacity to lower risks of various diseases.
Speaking to the BBC, Prime Minister Rishi Sunak emphasized the potential of such measures to aid individuals in returning to work, while reducing the strain on the NHS.
Health Secretary Wes Streeting noted these injections, including drugs like Mounjaro, could revolutionize treatment and alleviate NHS burdens, which see £11bn annually due to obesity-related illnesses.
A £279 million investment from pharmaceutical giant Lilly was announced at an international summit, with real-world trials to be conducted by Health Innovation Manchester and Lilly.
These trials will assess the impact of weight-loss jabs on employment and NHS usage.
Streeting further stressed that although the jabs could decrease absence due to obesity-related sickness, individuals must still prioritize healthy living.
Existing medicines, such as Wegovy and Ozempic, are administered via injection to aid appetite suppression, but experts advise that they should supplement, not replace, a healthy lifestyle.
NHS chief Amanda Pritchard described these drugs as potential 'game-changers', with the capacity to lower risks of various diseases.
